Evdokia Pasheva

1.0k total citations
33 papers, 886 citations indexed

About

Evdokia Pasheva is a scholar working on Molecular Biology, Clinical Biochemistry and Oncology. According to data from OpenAlex, Evdokia Pasheva has authored 33 papers receiving a total of 886 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 10 papers in Clinical Biochemistry and 8 papers in Oncology. Recurrent topics in Evdokia Pasheva's work include Genomics and Chromatin Dynamics (10 papers), Advanced Glycation End Products research (10 papers) and RNA Interference and Gene Delivery (7 papers). Evdokia Pasheva is often cited by papers focused on Genomics and Chromatin Dynamics (10 papers), Advanced Glycation End Products research (10 papers) and RNA Interference and Gene Delivery (7 papers). Evdokia Pasheva collaborates with scholars based in Bulgaria, France and Austria. Evdokia Pasheva's co-authors include Iva Ugrinova, Iliya G. Pashev, Alain Favre, Jean Armengaud, Georgi M. Dobrikov, A Tavitian, Isabelle Janoueix‐Lerosey, Jean de Gunzburg, Violeta Valcheva and Bettina Sarg and has published in prestigious journals such as Journal of Biological Chemistry, Biochemistry and Biochemical and Biophysical Research Communications.

In The Last Decade

Evdokia Pasheva

32 papers receiving 875 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Evdokia Pasheva Bulgaria 18 474 418 189 139 80 33 886
Matthew J. Toth United States 17 1.0k 2.2× 186 0.4× 113 0.6× 91 0.7× 41 0.5× 20 1.3k
Eileen S. Walsh United States 17 508 1.1× 114 0.3× 91 0.5× 208 1.5× 51 0.6× 20 844
Voraratt Champattanachai Thailand 17 826 1.7× 87 0.2× 385 2.0× 57 0.4× 94 1.2× 37 1.1k
Maria Antonietta Di Noia Italy 12 624 1.3× 203 0.5× 60 0.3× 57 0.4× 60 0.8× 20 831
Maria A Graziewicz United States 13 950 2.0× 308 0.7× 25 0.1× 43 0.3× 111 1.4× 15 1.1k
Željka Vukelić Croatia 22 952 2.0× 96 0.2× 53 0.3× 33 0.2× 119 1.5× 47 1.2k
Carl Kutzbach Germany 12 670 1.4× 222 0.5× 28 0.1× 72 0.5× 59 0.7× 16 1.2k
Garth B. Robinson United Kingdom 15 443 0.9× 95 0.2× 34 0.2× 85 0.6× 30 0.4× 40 825
Herman J. Sips Netherlands 14 331 0.7× 138 0.3× 27 0.1× 111 0.8× 20 0.3× 26 715
A Haeffner France 6 636 1.3× 25 0.1× 203 1.1× 109 0.8× 99 1.2× 7 930

Countries citing papers authored by Evdokia Pasheva

Since Specialization
Citations

This map shows the geographic impact of Evdokia Pasheva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evdokia Pasheva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evdokia Pasheva more than expected).

Fields of papers citing papers by Evdokia Pasheva

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evdokia Pasheva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evdokia Pasheva. The network helps show where Evdokia Pasheva may publish in the future.

Co-authorship network of co-authors of Evdokia Pasheva

This figure shows the co-authorship network connecting the top 25 collaborators of Evdokia Pasheva. A scholar is included among the top collaborators of Evdokia Pasheva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evdokia Pasheva. Evdokia Pasheva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ugrinova, Iva & Evdokia Pasheva. (2016). HMGB1 Protein. Advances in protein chemistry and structural biology. 107. 37–76. 51 indexed citations
2.
Ugrinova, Iva, et al.. (2016). Non-histone protein HMGB1 inhibits the repair of damaged DNA by cisplatin in NIH-3T3 murine fibroblasts. BMB Reports. 49(2). 99–104. 9 indexed citations
3.
Gospodinov, Anastas, et al.. (2016). The repair capacity of lung cancer cell lines A549 and H1299 depends on HMGB1 expression level and thep53status. The Journal of Biochemistry. 160(1). 37–47. 25 indexed citations
4.
Dobrikov, Georgi M., et al.. (2014). Antimycobacterial activity generated by the amide coupling of (−)-fenchone derived aminoalcohol with cinnamic acids and analogues. Bioorganic & Medicinal Chemistry Letters. 24(21). 5030–5033. 13 indexed citations
5.
Dobrikov, Georgi M., et al.. (2014). Enantiopure antituberculosis candidates synthesized from (−)-fenchone. European Journal of Medicinal Chemistry. 77. 243–247. 17 indexed citations
6.
Ugrinova, Iva, et al.. (2012). The effect of PKC phosphorylation on the “architectural” properties of HMGB1 protein. Molecular Biology Reports. 39(11). 9947–9953. 6 indexed citations
7.
Ugrinova, Iva, et al.. (2011). The DNA Binding and Bending Activities of Truncated Tail-less HMGB1 protein are Differentially Affected by Lys-2 and Lys-81 Residues and Their Acetylation. International Journal of Biological Sciences. 7(6). 691–699. 23 indexed citations
8.
Pasheva, Evdokia, et al.. (2011). High mobility group B1 protein interacts with its receptor RAGE in tumor cells but not in normal tissues. Oncology Letters. 3(1). 214–218. 45 indexed citations
9.
Momekov, Georgi, et al.. (2010). In vitro pharmacological study of monomeric platinum(III) hematoporphyrin IX complexes. Investigational New Drugs. 29(5). 742–751. 20 indexed citations
10.
Ugrinova, Iva, et al.. (2009). The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Molecular and Cellular Biochemistry. 337(1-2). 251–258. 114 indexed citations
11.
Ugrinova, Iva, et al.. (2009). Native HMGB1 protein inhibits repair of cisplatin-damaged nucleosomes in vitro. The International Journal of Biochemistry & Cell Biology. 41(7). 1556–1562. 36 indexed citations
12.
Pashev, Iliya G., et al.. (2009). Interplay between in vitro acetylation and phosphorylation of tailless HMGB1 protein. Biochemical and Biophysical Research Communications. 380(1). 138–142. 10 indexed citations
13.
Ugrinova, Iva, Iliya G. Pashev, & Evdokia Pasheva. (2009). Nucleosome Binding Properties and Co-Remodeling Activities of Native and in Vivo Acetylated HMGB-1 and HMGB-2 Proteins. Biochemistry. 48(27). 6502–6507. 35 indexed citations
14.
Ugrinova, Iva, Iliya G. Pashev, & Evdokia Pasheva. (2008). Post-synthetic acetylation of HMGB1 protein modulates its interactions with supercoiled DNA. Molecular Biology Reports. 36(6). 1399–1404. 19 indexed citations
15.
Ugrinova, Iva, et al.. (2007). HMGB1 protein inhibits DNA replication in vitro: A role of the acetylation and the acidic tail. The International Journal of Biochemistry & Cell Biology. 40(8). 1536–1542. 44 indexed citations
16.
Pasheva, Evdokia, et al.. (2002). The binding affinity of HMG1 protein to DNA modified by cis-platin and its analogs correlates with their antitumor activity. The International Journal of Biochemistry & Cell Biology. 34(1). 87–92. 17 indexed citations
17.
Ugrinova, Iva, Evdokia Pasheva, Jean Armengaud, & Iliya G. Pashev. (2001). In Vivo Acetylation of HMG1 Protein Enhances Its Binding Affinity to Distorted DNA Structures. Biochemistry. 40(48). 14655–14660. 55 indexed citations
18.
Janoueix‐Lerosey, Isabelle, et al.. (1998). Identification of a specific effector of the small GTP‐binding protein Rap2. European Journal of Biochemistry. 252(2). 290–298. 49 indexed citations
19.
Pasheva, Evdokia, Iliya G. Pashev, & Alain Favre. (1998). Preferential Binding of High Mobility Group 1 Protein to UV-damaged DNA. Journal of Biological Chemistry. 273(38). 24730–24736. 85 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Matthew J. Toth Breakdown of academic impact, for papers by Eileen S. Walsh Breakdown of academic impact, for papers by Voraratt Champattanachai Breakdown of academic impact, for papers by Maria Antonietta Di Noia Breakdown of academic impact, for papers by Maria A Graziewicz Breakdown of academic impact, for papers by Željka Vukelić Breakdown of academic impact, for papers by Carl Kutzbach Breakdown of academic impact, for papers by Garth B. Robinson Breakdown of academic impact, for papers by Herman J. Sips Breakdown of academic impact, for papers by A Haeffner
Rankless by CCL
2026